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The intensifying pressure on reducing the development timefor new
pharmaceutical products is resulting in an increasing need for
laboratory automation. A key element for the successful imple-
mentation of roboticsfor drug product analysis is the establishment
of a reliable processfor interaction of the automation team with its
various customers, for example development product team and
manufacturing group. The reduction of cycle time for product
development appears to be resulting in more stability studies to
support NDA/MAA filings for several reasons. Key clinical
information may not be available before initiation of the stability
studies and simultaneous world-wide development may result in an
increase in the number ofproduct strength and pack options.
Introduction
status of projects in the development pipeline. The results
of this process lead to a prioritized list of projects for the
team to develop and validate methods. As a central
support team there is inherent difficulty in finding a
time-efficient way of keeping up to date with changes
in projects that may affect work on the projects. This may
include changes in dosage form strength, in formulation
and in project timings as the results from the clinical
trials become available. More recently, it has been found
that central budgets for projects have been a good
reflection of changes and this is used to keep up to date
with the projects.
The destination of a product for commercial manufacture
is an important consideration. Discussions are held with
the manufacturing site to determine if there are any
unforeseen problems in their ability to use the automated
methods. In some instances particular sites may not have
the appropriate equipment to take on the automated
method and early notification will enable budgets to
include purchase of the required equipment.
Pharmaceutical Technologies at SmithKline Beecham
(SB) is responsible for the formulation and analytical
development, clinical trials supply and technology trans-
fer of new products to manufacturing facilities. The
department is organized with a team-based structure in
which the formulation and analytical development is
performed by dedicated ’product’ teams for a develop-
ment candidate. More generalized activities, such as
microbiological and raw materials’ testing, are the
responsibility of ’support’ teams. Implementing robotics/
automation is the mandate of the Analytical Technol-
ogies Development (ATD) Support team (see figure 1).
This central team works with the Product teams to
implement robotic analytical methods employing the
general process shown in figure 2 using the following
equipment: Zymark TPWTM IIs, Zymark MultiDoseTM
(USP2) and Zymate
TM dissolution robot (USP 1). Over
the past six to 12 months improvements to the imple-
mentation of this process have been identified and are
discussed below.
Discussion
Survey projects
Before work on automating products is initiated, periodic
surveys are performed to update information on the
Prioritize and plan
Once a listing of projects has been obtained, the timings
for automation need to be identified. Currently, samples
for NDA/MAA stability studies are being targeted for
robotics. However, this timing has been found to be too
late in some instances since Product teams can be too
busy to adopt the automated method as resources are
being used to support other activities such as the manu-
facture of the qualifying batches. Consequently, the goal
is to automate products sooner than Phase 2B/3 in the
development cycle to overcome this problem, however,
this needs to be balanced against late changes in strength
and formulation that can occur resulting in wasted effort
on automating redundant formulations.
In addition, the collection of metrics on the key elements
of the process described in figure 2 has been initiated to
provide data on the effort required to implement robotic
methods. This will enable a better assessment of the
overall benefit of using robotic methods for ’smaller’
projects. Estimation has also been made of the cost
benefit to production sites of the provision of ready
validated robotic methods (see table 1). In the future,
it is planned that implementation of robotic methods will
be rapid enough to make it cost effective to automate
projects from Phase I.
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Figure 1. Organizational structure.
Figure 2. Implementation process for robotic automation.
Table 1. Relative cost benefit of manual and automated methods.
Method type Time (h) Cost ()
Manual 22.5 (3 days) 1350
Automated 7.5 (1 day) 450
JV01e: Based on two analysts @ 30 per hour each.
@stems development
For the majority of the automation projects, the
Zymate
TM dissolution robot, Zymark Tablet TPWIITM
and Zymark MultiDoseTM dissolution systems are the
turnkey instruments used so there is little need for system
development. It is envisaged that this equipment will be
routinely used by the Product teams with involvement
from the Analytical Technologies Development (ATD)
team only when problems occur and troubleshooting is
needed. The ATD team is responsible for ensuring that
the equipment used is qualified appropriately, which
may involve working with the vendor of the instrumenta-
tion for turnkey systems for performing the work intern-
ally for customized equipment.
The next generation of automated systems will need to
increase the speed of analysis for pharmaceutical dosage
forms. First, there will be increase in development candi-
dates generated by Discovery as a result of technologies
like combinatorial chemistry. Second, there has been an
increase in the number of stability studies as a result of
parallel development and global commercialization of
products. For example, for some indications, special
packaging and dose strengths are needed by Japan.
Also, in commercial operations there is an increased
need for flexibility in the supply chain, which has resulted
in extra stability studies to support change in manu-
facturing site.
The result of these trends has been that on average
during development of a solid oral dosage form for a
single indication; four strengths of tablet are formulated
and three pack options are qualified for marketing,
culminating in 150-250 stability studies being performed.
Clearly this is a massive resource load that automation
must help reduce. To further exacerbate this situation
when stability samples are taken off store the analyses
need to be completed in a specified timeframe. For one
SB product, 100 dissolutions, 100 assays and 100 degra-
dation profiles needed to be performed in 10 working
days. Automated dissolution equipment is necessary to
complete this task.
Reducing the turnaround time for analyses to meet the
increasing workload could be achieved by developing the
following technologies:
Fibre optics for in situ analysis. This technology has
been already been implemented by other workers
[1] for dissolution procedures and could, in prin-
ciple, be applied to content uniformity and assay
methods.
Systems of reduced size to facilitate on-line/at-line
analysis. This is particularly important for USP1
dissolution where fully automated robotic units
can take up a lot of space.
Faster analysis by using technologies such as micro
liquid chromatography and capillary electrochro-
matography. Also, with the development of cheaper
and more user-friendly LC/MS systems, it may be
feasible to follow the lead shown in the analysis of
biofluids and employ this technology for rapid
analysis of drugs in dosage forms particularly for
highly potent low dose products. The successful
use of these technologies would reduce runtimes
for analysis from about 15min down to about
3min. As a consequence, the speed of sample
preparation, typically 20 min for the Zymark
TPWIITM, would be the rate limiting for on-line
analysis and significant improvements in this are
needed.
Improved links between robotics and LIMS systems
to enable easier movement of data is critical. This is
particularly important for the extra data available
from robotic systems (for example sample weights,
solvent volumes, dilution volumes, etc.) that are
currently archived separately from the assay result
information which is stored in LIMS. Ideally, these
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Table 2. Generic extraction solvents.
Aqueous solubility of
drug (mg/ml) Extraction solvent
> Aqueous buffer
1-0.05 Methanol/aqueous buffer
< 0.05 High methanol content
data should be available for review from the LIMS
system for audit purposes.
Method development
In order to promote the use of robotics, it is intended to
provide method development guidelines for the Zymark
TPWIITM which should also give a better understanding
of the requirements for automated methods and promote
method harmonization. Currently, the extraction system
for automated methods is based on that already available
for the manual procedure which has resulted in some
instances in significantly different extraction solvents
being used for compounds from a similar class or for
product line extensions of the same compound. For one
major project, six different extraction solvent/conditions
are used for solid oral dosage forms. The goal is to move
towards preferred extraction solvent conditions for com-
pounds depending on its solubility as shown in table 2. It
is intended that these solvent conditions are employed
first, if this is not successful, alternative solvents are
investigated.
Manual methods typically use shaking and ultrasonica-
tion procedures for extraction of the drug from the
formulation matrix. It may be appropriate to suggest
investigation ofhomogenization as an alternative manual
procedure in the method development guidelines to
enable easier transfer of methods to the TPWIITM.
Experimental design is also being used to optimize the
Zymark TPWIITM extraction procedure. The success of
this technique is dependent on real differences being
observed in the results. For example, it has been found
that the inherent variation in the assay of a batch ofdrug
product can provide misleading conclusions on the sig-
nificance of an extraction parameter. Increasing the
replication for each set of conditions avoids this phenom-
enon. Also, occasional spuriously low results have been
obtained and interrogation of the audit trail reveals no
obvious reason can be determined leading to confound-
ing of the results. It is suspected that incomplete break-up
of tablet may be the reason, but there is no evidence to
support this hypothesis. Monitoring of the extraction
vessel during optimization of the extraction using a
video camera could help in problem diagnosis.
The responsibility for development of robotic methods
currently lies with the ATD team. As Product teams
become more familiar with the technology, and as the
guidelines for automated methods become available, it is
intended that the responsibility for this step in the process
moves towards the Product team with the ATD team
acting in a consultative capacity.
The possibility of contracting out this function is also
being investigated to enable faster implementation of
automated methods, this will become particularly im-
portant as new technologies, like combinatorial chemis-
try, result in more compounds entering development
which, in turn, will mean the automated method devel-
opment capacity of Pharmaceutical Technologies being
exceeded. It may also be appropriate to have robotic
methods developed by contractors for more ’mature’
products with long tedious extraction procedures (for
example controlled release products).
Method agreed with customer
On the completion of development of the method, feed-
back is obtained from the Product team to ensure the
procedure satisfies their needs. For MAA/NDA stability
studies, the aim is to provide a suite of automated
methods including assay, degradation profile and dissolu-
tion procedures. Agreement is also sought from Produc-
tion to ensure, where feasible, that requirements have
been met. In the commercial environment, the emphasis
for automation is on the release testing of product,
whereas, in Research and Development, automation of
stability testing methodology is the priority. For example,
in Pharmaceutical Technologies there is a general pre-
ference for HPLC methods for assay, whereas some
Production sites have a preference for UV procedures
for ’stable’ compounds. For assay methods using the
Zymark TPWIITM the rate limiting step is the speed of
the sample preparation rather than analysis since the
time for the HPLC or UV assay does not add signifi-
cantly to the overall analysis time.
Validation protocol
Validation protocols [2] are agreed with the Product
team before work is initiated, so the appropriate samples
and resource can be provided. As more experience is
obtained, it is anticipated the protocols will become
generic with little variation from product to product.
It has been found the acceptance criteria for the compar-
ison of the assay results from the manual and automated
methods need to be carefully selected. Reliance on sta-
tistical tests has caused problems for two reasons. First,
the precision of the automated procedure can be signifi-
cantly better than the manual procedure. Second, the
homogeneity of the batch of drug product used for
showing equivalence to the manual method may be
variable enough for statistical differences to be found,
particularly for low dose compounds. The acceptance
criterion generally used is that the mean of the manual
and robotic results must agree within 2.0%. Ideally from
a statistical viewpoint it is desirable to test six batches for
comparison purposes, however, during the development
of a product there are limited numbers of batches avail-
able to compare the automated and manual methods. A
pragmatic approach has been taken ensuring at least one
batch of the highest and lowest strengths of the drug
product are tested for the comparison.
Method validation
Currently, method validation is performed by the ATD
team since the robotic technology is relatively new to the
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department. Earlier implementation of automated pro-
cedures (for example Phase 2A), together with the poss-
ibility of seconding a member of the Product team into
the ATD team to perform method validation will be
investigated. Using a contract laboratory for this work
will also be examined. In the long term, with the
availability of validation guidelines for automated
methods and increased familiarity with the equipment,
it is envisaged that the Product teams will have the
expertise to perform this task. This should significantly
increase the rate at which new methods can be intro-
duced.
In the UK, an inter-company pharmaceutical group is
developing a common set of validation guidelines for
assay/content uniformity and dissolution testing. YVhen
agreed, it is planned to publish these guidelines.
Validation report
The completion of the validation report for the auto-
mated method is a key deliverable that needs to be
completed before the automated method can be used.
Currently the onus is on the ATD team to generate this
report. The validation report produced is approved by
the ATD and the Product teams. It is the Product team’s
responsibility to incorporate the information into their
existing report for the manual method. Generic templates
for validation reports should be available as more
methods are validated. This should speed up the rate at
which the ATD team can complete this task.
Method transfer
In order to transfer methods successfully, training of the
Product teams on the automated systems is a critical
aspect of the ATD team’s role. The user friendliness
of the robotic systems has improved, particularlyr, with
qM IM the introduction of the Benchmate /TPWlI /Multi-
Dose
TM systems. However, unless these systems are used
on a regular basis, familiarity and ease of use will be lost.
It has been found that retraining of Product teams
occurs too frequently. Consequently, the drive to
establish automated methodology earlier in the product
development process is a priority.
Transfer of automated methods to SB production facil-
ities should be a relatively simple process, i.e. a method
on a computer disk. The Production sites have invested in
robotic equipment to gain not only cost savings [3] but
also to reduce the method transfer time and resource.
The protocol to transfer of the automated method from
site to site is generally based on comparing data from at
least three batches of drug product. The acceptance
criterion is that the mean of the results is within 2.0%.
The manufacturing sites have found robotic methods to
be generally more robust than manual procedures.
In order to gain most benefit from robotics, it is import-
ant that commercial manufacturing sites have the same
type of robotic equipment as that used by Research and
Development. The method development and validation
performed in Pharmaceutical Technologies can be used
by production sites, which results in reduced time and
resource in transferring methods. For major projects,
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more than one site is often involved in commercial
manufacture, so proportionately greater savings are gen-
erated. Production sites within SB have recognized these
advantages and have invested in the same robotic plat-
forms which comprise Zymark TPWIITM and Multi-
DoseTM systems. In order to co-ordinate automation
activities between Pharmaceutical Technologies and Pro-
duction, regular communication is achieved through
teleconferences and, in the future, a database will be
implemented to aid sharing of information. For example
updates on the status projects in Research and Develop-
ment and on equipment evaluations will be given.
Contract laboratories are now beginning to invest in
robotics and outsourcing stability testing using auto-
mated methods is being actively investigated. It is antici-
pated that the same type of cost savings described above
for the transfer of methods to SB Production facilities will
be achieved.
Customer feedback
In the past, the reliability of our robotic systems has been
poor, resulting in the Product team becoming frustrated
with the systems and turning back to their manual
methods. More recently, however, with advent of up-
grades in software and purchase of newer equipment,
reliability has reached a level that does not seem to affect
the user significantly. Metrics are now being collected
using the key steps in the process described in figure 2,
including the time taken to develop and validate robotic
methods, together with logging of the number of samples
run on the automated equipment. This should provide
information on improvements in the implementation
process for automated methods and should also generate
data to help justify future equipment purchases. As
mentioned above, meetings have been initiated with
Production to understand their needs and to obtain
feedback on methods that have been transferred.
Summary
A process for the implementation of robotics for product
analysis has been defined and improvements highlighted.
Major Phase 2/3 products are targeted for robotics and
these methods are used for stability studies to support
regulatory filings. The reduction of cycle time and world-
wide product development appears to be resulting in
more stability studies to support NDA/MAA filings.
Implementation of technologies to reduce the analysis
time have been outlined, which will result in the require-
ment to increase the speed of sample preparation.
Technology transfer of robotic analytical methods to
manufacturing is relatively simple, providing the QC
laboratories at the commercial production site make the
strategic decision to align their robotic equipment with
that available in Development. At present few contract
testing laboratories have robotic automation available,
which restricts outsourcing of large stability studies using
this technology.Nigel North and Simon Smith Laboratory automation
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